Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Total Current Liabilities came in at $15.6 billion in Q2 2026, up 31.91% YoY from $11.9 billion in Q2 2025, and up 15.62% on a QoQ basis from $13.5 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Total Current Liabilities data on file, last reported at $15.6 billion in Q2 2026.
- Quarterly Total Current Liabilities rose 31.91% year-over-year to $15.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.6 billion (up 31.91% YoY) and the FY2025 annual result came in at $13.5 billion, up 5.16% from the prior year.
- Total Current Liabilities improved to $15.6 billion in Q2 2026, from $13.5 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $15.6 billion in Q2 2026 to a low of $10.4 billion in Q1 2023.
- A 5-year average of $12.3 billion and a median of $11.9 billion in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities soared 32.48% — and 2025, when it dropped 19.11%.
- Tracing TEVA's Total Current Liabilities over 5 years: stood at $11.5 billion in 2022, then gained by 6.78% to $12.2 billion in 2023, then advanced by 4.48% to $12.8 billion in 2024, then increased by 5.16% to $13.5 billion in 2025, then grew by 16.28% to $15.6 billion in 2026.
- The last three Total Current Liabilities figures came in at $15.6 billion (Q2 2026), $13.5 billion (Q1 2026), and $13.5 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 1.79 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.65 Bn |
| Mar 31, 2026 | 13.53 Bn |
| Dec 31, 2025 | 13.46 Bn |
| Sep 30, 2025 | 11.49 Bn |
| Jun 30, 2025 | 11.86 Bn |
| Mar 31, 2025 | 11.16 Bn |
| Dec 31, 2024 | 12.80 Bn |
| Sep 30, 2024 | 13.80 Bn |
| Jun 30, 2024 | 13.04 Bn |
| Mar 31, 2024 | 13.79 Bn |
| Dec 31, 2023 | 12.25 Bn |
| Sep 30, 2023 | 11.39 Bn |
| Jun 30, 2023 | 11.84 Bn |
| Mar 31, 2023 | 10.41 Bn |
| Dec 31, 2022 | 11.47 Bn |
| Sep 30, 2022 | 11.53 Bn |
| Jun 30, 2022 | 11.00 Bn |
| Mar 31, 2022 | 11.61 Bn |
| Dec 31, 2021 | 11.03 Bn |
| Sep 30, 2021 | 11.83 Bn |